ISPOR Panelists Discuss Incorporating the Patient Voice in Prescription Drug Value Assessments

In a recent virtual ISPOR meeting, panelists discussed how to adjust methods such that patient experiences can be better incorporated into value assessments, along with quality-adjusted life year (QALY) and other metrics. When and how patient data is utilized can drastically affect the value assessment of a drug, making this discussion thought-provoking for payers, pharma, researchers, and other stakeholders.

“Melanie Whittington, Ph.D., M.S., the associate director of health economics at the Institute of Clinical and Economic Review (ICER), the influential value-assessment organization in Boston, said ICER contacts patient groups before it publicly announces it is going to conduct a review and involves the groups as it decides the scope of its review and which clinical outcomes to consider. “As a modeler, this is always a great opportunity for me to figure out what matters most to patients to make sure that is captured, to the extent possible, in the model,” she said. Read more here.

(Source: Peter Wehrwein, Managed Healthcare Executive, 5/17/21)